Access to Drug Treatments
This page has the latest updates about plans to manage the impact of COVID-19 on the Managed Access Agreement (MAA) for nusinersen treatment in England and any other updates from the devolved nations.
It will also cover, or have links to, any updates about access to the other treatments, risdiplam and ZolgensmaTM.
ZOLGENSMA: REQUEST TO NICE TO INCLUDE appraisal as a therapeutically critical topic in COVID-19 IMPacted Work Programme
Nusinersen MAA: Statement from NHS England and NICE
BIOGEN'S STATEMENT RE: CORONAVIRUS (COVID-19) IMPACT on access to nusinersen
ROCHE’S CLINICAL DEVELOPMENT PROGRAMME STATEMENT RE: CORONAVIRUS (COVID-19) IMPACT on risdiplam trials and global access programme